retarded. Calmodulin antagonists, including W-7, compound 48/80 , and trifluoper-
azine, have been used to inhibit activities of CDPK. However, these compounds
cannot rule out the possibility of participation of other calcium-regulated kinases,
including CBL-regulated CIP K (Kudla et al. 2010), and CRK (for CDPK-related
kinase) (Zhang and Lu 2003). Apicomplexan parasites are a diverse group of
protozoan parasites, several of which cause important human and animal diseases,
including malaria. Because humans do not have CDPKs, CDPK-specific inhibitors
would be effective drugs against apicomplexan parasites. Toxoplasma gondii
CDPK (TgCDPK1), which plays a key role in parasite invasion, contains a unique
sequence variation in the ATP-binding pocket o f the catalytic domain: namely, a
Gly at the so-called “gatekeeper position.” This variation distinguishes TgCDPK1
from other kinases, including TgCDPK3, and plant CDPKs. BKIs (for bumped
kinase inhibitors) are analogs of 4-amino-1- tert-butyl-3-phenylpyrazolo[3,4-
D]
pyrimidine) that are derivatized at the C3 position with bulky aromatic groups
(Bishop et al. 1999). Large gatekeeper residues, such as Met, severely restrict the
access of BKIs to the ATP-binding pocket, whereas small gatekeeper residues, such
as Gly present in TgCDPK1, allow the access of BKIs to the ATP-binding pocket.
BKIs inhibited both activities of TgCDPK1 and parasite inva sion to human cells
without affecting kinases of host cells (Ojo et al. 2010 ). Plant CDPKs are insensi-
tive to BKIs; however, replacement of a plant CDPK gene with its mutant version in
which the large amino acid residue at the gatekeeper position is substituted to Gly,
would allow phenotypic investigation of the effects of the specific inhibition of the
CDPK by BKIs. This is the so-called ASK A (for analog-sensitive kinase allele)
approach (Bishop et al. 2000). Alternatively , because the junction domain and
calmodulin-like domain of CDPK work together on Ca
2+
binding unlike other
proteins containing EF hands, including CaM (Wernimont et al. 2010), this unique
mechanism of activation could be the effective target to inhibit CDPKs selectively.
Inducible knockdown of a CDPK by RNAi might be useful to reveal functions of
CDPKs in vivo, since the complete removal of CDPKs that play critical roles in
development might result in lethality.
Although CDPKs have been reported to be involved in diverse physiological
processes, very limited information is available about the direct substrates in vivo.
Ito et al. (2010) showed that the variable N-terminal domain of NtCDPK1 is
directly involved in the recognition of the target protein. In Arabidopsis, CDPKs
comprise a protein family with 34 members, all of which, except for CPK26, have a
variable N-terminal domain consisting of 25–180 amino acids in length. Yeast two-
hybrid analysis suggested that the variable N-terminal domain of an Arabidopsis
CDPK, CPK32, participates in the interaction with transcription factor ABF4 (Choi
et al. 2005). If the variable N-terminal domain of other CDPKs, as well as that of
NtCDPK1, play roles in substrate recognition, the search for interacting prot eins of
the variable N-terminal domain by yeast two-hybrid screen or the TAP tag purifi-
cation method would provide important clues to identify the physiological
substrates of each CDPK. Phosphoproteomics has enabled large-scale identification
of protein phosphorylation sites, benefiting from advances in phosphor peptide
enrichment and improvements in mass spectrometry (Ville
´
n and Gygi 2008).
Structure and Function of CDPK: A Sensor Responder of Calcium 141